Core Insights - L'Oréal has finalized the acquisition of a majority stake in the British high-end skincare brand Medik8, integrating it into its luxury cosmetics division [1][3] - The acquisition contradicts earlier reports suggesting Medik8 would join L'Oréal's skin science and beauty division [1][13] Company Overview - Medik8 was founded in 2009 by Elliot Isaacs, a renowned pharmacologist and biochemist, focusing on innovative skincare solutions for common skin issues [7][10] - The brand has established partnerships with thousands of professional skin therapy clinics and high-end spas, employing over 300 staff and selling products in over 7,000 professional clinics [7][12] Financial Performance - Medik8 is projected to achieve a 50% year-on-year sales growth in 2024, with global revenue expected to reach $115 million (approximately 826 million RMB) in 2025 [12] - The acquisition amount is speculated to be around €1 billion (approximately 8.2 billion RMB), although L'Oréal has not confirmed this figure [12][19] Strategic Implications - The acquisition aims to enhance L'Oréal's luxury cosmetics division, which has faced slowing growth, with recent sales growth rates dropping to single digits [15][18] - Medik8's strong performance in the efficacy skincare sector and its established market presence are expected to provide L'Oréal with a competitive advantage in the high-end market [19]